Literature DB >> 24113792

Two targets for the price of one.

Stephen M Ansell1.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 24113792     DOI: 10.1182/blood-2013-08-518548

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

Review 1.  Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Authors:  Amin Aalipour; Ranjana H Advani
Journal:  Ther Adv Hematol       Date:  2014-08

2.  Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

Authors:  C S Link; R Teipel; F Heidenreich; E Rücker-Braun; M Schmiedgen; J Reinhardt; U Oelschlägel; M von Bonin; J M Middeke; A Muetherig; K Trautmann-Grill; U Platzbecker; M Bornhäuser; J Schetelig
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

3.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

4.  Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.

Authors:  Andrew Stiff; Prashant Trikha; Robert Wesolowski; Kari Kendra; Vincent Hsu; Sarvani Uppati; Elizabeth McMichael; Megan Duggan; Amanda Campbell; Karen Keller; Ian Landi; Yiming Zhong; Jason Dubovsky; John Harrison Howard; Lianbo Yu; Bonnie Harrington; Matthew Old; Sean Reiff; Thomas Mace; Susheela Tridandapani; Natarajan Muthusamy; Michael A Caligiuri; John C Byrd; William E Carson
Journal:  Cancer Res       Date:  2016-02-15       Impact factor: 12.701

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.